Compare Etsy Inc (ETSY) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Etsy Inc trades at $82.12 (market cap $7.61B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Etsy Inc and Spyre Therapeutics Inc. Common Stock are close in size by market cap, and Etsy Inc is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Etsy Inc for 67 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| ETSY | SYRE | |
|---|---|---|
Market Cap | $7.61B | $7.35B |
Volume | 3,831,386 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $87.03 | $108.92 |
52-Week Low | $44.05 | $22.18 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | $9.56B | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $79.28, up 3.05% today, with a bullish technical signal and strong institutional interest. Recent earnings beats and a 71.4% gross margin highlight operational strength, though net income margin compressed to 5.65% in 2025. The stock is near its consensus price target of $85.94, with positive sentiment driven by AI initiatives and partnership renewals.
Outlook is cautiously optimistic given analyst support and growth initiatives, but risks include high debt-to-asset ratio (105.48% in 2025) and competitive e-commerce pressures. Upside hinges on AI-driven personalization boosting revenue, while margin pressure and macroeconomic headwinds pose challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
